Optimum anthracycline-based chemotherapy for early breast cancer

Adjuvant chemotherapy improves the overall survival of women treated after surgery for early breast cancer. Several trials have suggested that anthracycline-containing regimens are more effective than those that do not contain anthracyclines. A modest overall benefit has also been confirmed by the E...

Full description

Saved in:
Bibliographic Details
Published inThe lancet oncology Vol. 2; no. 8; pp. 469 - 474
Main Authors Adlard, Julian W, Dodwell, David J
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.08.2001
Elsevier Limited
Subjects
Antibiotics, Antineoplastic - therapeutic use
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Breast cancer
Breast Neoplasms - drug therapy
Breast Neoplasms - pathology
Cisplatin - therapeutic use
Female
Fluorouracil - therapeutic use
Humans
Methotrexate - therapeutic use
Neoplasm Staging
Online AccessGet full text

Cover

More Information
Summary:Adjuvant chemotherapy improves the overall survival of women treated after surgery for early breast cancer. Several trials have suggested that anthracycline-containing regimens are more effective than those that do not contain anthracyclines. A modest overall benefit has also been confirmed by the Early Breast Cancer Trialists' Collaborative Group overview. Newer agents, such as the taxanes, are now being tested in the adjuvant setting in randomised trials. The control group of such studies should receive the optimum standard treatment. There are several anthracycline-based regimens in common use, varying in terms of the type of anthracycline used, the dose, and drug scheduling. We review the available evidence and consider whether the optimum anthracycline-containing chemotherapy schedule has now been identified.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1470-2045
1474-5488
DOI:10.1016/S1470-2045(01)00452-1